Poland· PL-100538881
Zepzelca
A lurbinectedin product containing lurbinectedin, registered in Poland by Pharma Mar, S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lurbinectedin is registered in 8 of 19 countries.
Countries holding a registration under ATC L01XX69 (lurbinectedin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Lurbinectedin · ATC L01XX69
8 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Lurbinectedin
- Manufacturer
- Pharma Mar, S.A.
- Country
- Poland (PL)
- ATC code
- L01XX69
- ATC class
- Lurbinectedin
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin04150205923331
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
203 interactions on record for lurbinectedin.
Graded by severity as the source publishes them — 60 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lurbinectedin · interactions on record
203 records
- 60 severe
- 142 moderate
- 1 minor
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lurbinectedin in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZepzelca 2 mgPharma Mar
- CzechiaZEPZELCAPharma Mar, S.A., Madrid
- SpainZEPZELCA 2 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONPharma Mar S.A.
- FinlandZepzelcaPharma Mar S.A.
- SwedenZepzelca 2 mg Pulver till koncentrat till infusionsvätska, lösningPharma Mar SA
- NetherlandsZEPZELCA 2 mg poeder voor concentraat voor oplossing voor infusiePharma Mar S.A.
- CanadaZEPZELCAJAZZ PHARMACEUTICALS IRELAND LIMITED
- SwitzerlandZepzelca 4 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungPharmaMar AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zepzelca
- Liechtenstein · Zepzelca
- Norway · Zepzelca
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d217e230-577b-4863-a20c-ced32ac1e2c6 GET /v1/drugs/d217e230-577b-4863-a20c-ced32ac1e2c6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "2 mg",
"packaging": "Rpz ¦ EU/1/26/2032/001 ¦ 167606\n1 fiol. 20 ml\n¦ UR/Z/4b/228/26 - 04150205923331",
"substance": "Lurbinectedin 2 mg",
"common_name": "Lurbinectedin",
"pl_product_id": "100538881",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lurbinectedin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.